BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The partners could supply the WHO with coronavirus vaccine doses for lower-income countries.

Pfizer and BioNTech to Supply WHO's COVID-19 Vaccine Program

PFE stock never enjoyed the same run-up in the Covid-19 vaccine race as its competitors, even though it crossed the finish line first. The post For Pfizer, the Covid-19 Vaccine ‘Honeymoon' Is Over appeared first on InvestorPlace.

For Pfizer, the Covid-19 Vaccine ‘Honeymoon' Is Over

European countries should use all available vaccine doses provided by biotech firm BioNTech and its partner Pfizer because there will be enough for the requisite second booster shot due to a planned production ramp-up, BioNTech's largest investor said.

BioNTech investor, amid worry over shortage, vows vaccines to be delivered for second shot

A new study bolsters confidence in the mRNA vaccine.

Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant

The coronavirus vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) works against a new strain of coronavirus that appeared in the U.K., according to a preprint made available before publication. What Happened: The B.1.1.7 strain is unlikely to escape BNT162b2-mediated protection, according to the preprint.

Pfizer-BioNTech Vaccine Found Effective Against New Coronavirus Strain In Lab Study

New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine BNT162b2 to neutralize the SARS-CoV-2 U.K. strain, also known as B.1.1.7 lineage or VOC 202012/01. The results were published on the preprint server bioRxiv and submitted to a peer-reviewed journal.

Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

The Covid vaccine developed by Pfizer-BioNTech is likely to be effective against a mutant strain of the virus that was first discovered in the U.K.

Pfizer-BioNTech vaccine found to be effective against Covid variant discovered in the UK

New York Governor Andrew Cuomo asked Pfizer Inc (NYSE: PFE) to sell its COVID-19 vaccine directly to New York in a letter on Monday. What Happened: The governor wrote to the New York-based pharmaceutical giant's CEO Albert Bourla as Pfizer is not bound by supply commitments that rival Moderna Inc (NASDAQ: MRNA) has made under Operation Warp Speed — the federal government's vaccine initiative.

Cuomo Asks Pfizer To Let New York Purchase COVID-19 Vaccine Directly

New York Gov. Andrew Cuomo called on pharmaceutical company Pfizer to sell doses of its coronavirus vaccine directly to New York state, in the hopes of accelerating a process that has languished in recent weeks. The request would require Pfizer to circumvent the federal government's Operation Warp Speed — a campaign to produce and distribute some 300 million doses to Americans in an effort to end the pandemic — and deal directly with Cuomo's state administration.

Cuomo asked Pfizer to sell its COVID-19 vaccine directly to New York, just as the head of the WHO warns of mounting inequities in vaccine distribution

The request comes after an alarmingly slow start to the national vaccine rollout, with the country millions of injections short of initial projections.

New York Gov. Cuomo asks to buy Covid vaccine directly from Pfizer amid dose shortages

Pfizer will temporarily reduce the number of doses of its coronavirus vaccine being delivered to Europe, according to the Norwegian Institute of Public Health.

Pfizer to temporarily reduce Covid vaccine deliveries to Europe

Editas Medicine

SmileDirectClub

Just because they did it in 2020 doesn't mean they won't outrun the market again in the new year.

3 Healthcare Stocks That Can Double Your Money in 2021

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

Invesco Dynamic Biotechnology & Genome ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The companies also expect to apply their mRNA vaccine technology to other diseases, such as flu.

Pfizer, BioNTech Boost Vaccine Production Goal To 2 Billion Doses In 2021

Moderna

COVID-19 Vaccine Production to Ramp Up

"I think the main bottleneck right now is to make sure we ramp up our prioritization so we can administer more vaccines," Pfizer CEO Albert Bourla told CNBC.

Pfizer CEO supports expanding Covid vaccine eligibility, describes supply of doses as adequate

Its CEO is confident that the company's coronavirus vaccine can weather several big challenges it faces.

Why BioNTech Crushed the Market on Monday

BioNTech stock jumped Monday after the company said it plans to make 2 billion doses of its Pfizer-partnered coronavirus vaccine in 2021. J&J is reportedly aiming for 1 billion doses.

BioNTech Surges On Its Plan To Make 2 Billion Covid Vaccine Doses In 2021

Success would help Pfizer and BioNTech compete longer term with J&J and Novavax, whose vaccines don't have the same temperature restrictions.

BioNTech CEO Says a Version of Its Covid Vaccine With Less Stringent Storage Requirements Could Come This Year

Public health experts have expressed concern the new mutant strains could pose a threat to inoculation efforts.

BioNTech says Covid vaccine is effective against key new strains; to publish more data in days

Germany's BioNTech SE said Monday it is aiming to supply up to 2 billion doses of its COVID-19 vaccine in 2021, after receiving emergency use authorization in both the U.S. and EU. In a regulatory filing, the company said it has committed to supplying more than 1 billion doses of the vaccine, which it co-developed with Pfizer Inc..

BioNTech to target supply of up to 2 billion doses of COVID-19 vaccine in 2021

GW Pharmaceuticals

Taiwan Semiconductor Manufacturing

Add these top growth stocks to your portfolio before it's too late.

Your 3 Best Profit Opportunities in 2021

A mutating COVID-19 virus forces the world to cut corners on vaccine strategy. The Herd Immunity strategy has been unofficially suspended for a pressing need strategy.

Biontech SE: Mutating COVID Virus And An Evolving Competitive Vaccine Environment

The European Union is planning to double its supply of Pfizer's coronavirus vaccine by purchasing up to 300 million additional doses, officials said Friday. The deal would add to the EU's existing 300 million-dose order — potentially giving the 27-nation bloc nearly half of the 1.3 billion doses that Pfizer and German partner BioNTech plan.

EU looks to buy another 300 million doses of Pfizer COVID vaccine

BioNTech stock popped Friday after a small test showed its Pfizer-partnered coronavirus vaccine could work against more infectious variants plaguing the U.K. and South Africa. The post BioNTech Jumps As Study Suggests Covid Vaccine Might Block New Strains appeared first on Investor's Business Daily.

News for BioNTech SE Stock (BNTX)